- Home
- EVGO vs GOSS Comparison
EVGO vs GOSS Comparison
Compare EVGO & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGO
- GOSS
- Stock Information
- Founded
- EVGO 2010
- GOSS 2015
- Country
- EVGO United States
- GOSS United States
- Employees
- EVGO N/A
- GOSS N/A
- Industry
- EVGO Other Specialty Stores
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- EVGO Consumer Discretionary
- GOSS Health Care
- Exchange
- EVGO Nasdaq
- GOSS Nasdaq
- Market Cap
- EVGO 532.0M
- GOSS 586.6M
- IPO Year
- EVGO N/A
- GOSS 2019
- Fundamental
- Price
- EVGO $3.93
- GOSS $2.94
- Analyst Decision
- EVGO Strong Buy
- GOSS Strong Buy
- Analyst Count
- EVGO 10
- GOSS 4
- Target Price
- EVGO $6.10
- GOSS $8.50
- AVG Volume (30 Days)
- EVGO 3.7M
- GOSS 3.3M
- Earning Date
- EVGO 08-05-2025
- GOSS 11-06-2025
- Dividend Yield
- EVGO N/A
- GOSS N/A
- EPS Growth
- EVGO N/A
- GOSS N/A
- EPS
- EVGO N/A
- GOSS N/A
- Revenue
- EVGO $308,365,000.00
- GOSS $40,237,000.00
- Revenue This Year
- EVGO $45.45
- GOSS N/A
- Revenue Next Year
- EVGO $26.93
- GOSS $30.65
- P/E Ratio
- EVGO N/A
- GOSS N/A
- Revenue Growth
- EVGO 49.06
- GOSS N/A
- 52 Week Low
- EVGO $2.20
- GOSS $0.66
- 52 Week High
- EVGO $9.07
- GOSS $2.98
- Technical
- Relative Strength Index (RSI)
- EVGO 53.50
- GOSS 76.74
- Support Level
- EVGO $3.80
- GOSS $2.41
- Resistance Level
- EVGO $4.21
- GOSS $2.71
- Average True Range (ATR)
- EVGO 0.20
- GOSS 0.19
- MACD
- EVGO -0.02
- GOSS 0.04
- Stochastic Oscillator
- EVGO 37.21
- GOSS 96.37
About EVGO EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.